Adenosine Deaminase-Severe Combined Immunodeficiency Market

Market Overview:

The 7 major adenosine deaminase-severe combined immunodeficiency markets reached a value of US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.3 Billion by 2034, exhibiting a growth rate (CAGR) of 6.24% during 2024-2034.

The adenosine deaminase-severe combined immunodeficiency market has been comprehensively analyzed in IMARC's new report titled "Adenosine Deaminase-Severe Combined Immunodeficiency Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare inherited disorder characterized by a severely compromised immune system. This condition is caused by mutations in the adenosine deaminase gene that lead to a deficiency in the enzyme adenosine deaminase, which plays a critical part in the formation and function of immune cells, particularly T and B lymphocytes. Individuals suffering from ADA-SCID exhibit a range of severe symptoms due to their compromised immune systems. Recurrent and serious infections, often caused by bacteria, viruses, and fungi, are common. These infections can affect various organ systems and pose a substantial threat to the health and survival of the patient. Numerous other indications include failure to thrive, developmental delays, and immune-related complications. Diagnosing ADA-SCID involves clinical assessment, immunological testing, and genetic analysis. The healthcare provider might perform blood workups to reveal a marked depletion of T and B lymphocytes and functional tests to confirm the immune system's impaired responses.

The escalating cases of genetic conditions, causing mutations in the ADA gene, which lead to enzyme dysfunction and consequent immune system anomalies, are primarily driving the adenosine deaminase-severe combined immunodeficiency market. In addition to this, the inflating utilization of enzyme replacement therapy to combat the symptoms and manage the disorder is also creating a positive outlook for the market. Moreover, the widespread adoption of gene therapy, since it introduces corrected genes into cells to replace or amend the flawed genes underlying the condition, is further bolstering the market growth. Apart from this, the rising usage of bone marrow transplantation, a primary treatment modality that helps to restore a functional immune system, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of adoptive T-cell therapies, aimed at infusing the patient with functional T cells, thereby offering long-lasting immune restoration and improving the quality of life, is also augmenting the market growth. Furthermore, the increasing demand for non-conditioned stem cell transplantation procedures, since they ensure minimal side effects, shorter hospital stay as well as preservation of a patient's future ability to have children, is expected to drive the adenosine deaminase-severe combined immunodeficiency market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the adenosine deaminase-severe combined immunodeficiency market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for adenosine deaminase-severe combined immunodeficiency and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the adenosine deaminase-severe combined immunodeficiency market in any manner.

Recent Developments:

• In September 2023, Fondazione Telethon and Orchard Therapeutics reported the completion of the transfer of the marketing authorization for Strimvelis, a gene therapy licensed by the European Medicines Agency in 2016 for the treatment of adenosine deaminase severe combined immunodeficiency.

Key Highlights:

• Adenosine deaminase deficiency (ADA deficiency) is an uncommon genetic disorder that causes 10-15% of all cases of severe combined immunodeficiency (SCID).
• The global prevalence of ADA deficiency is believed to be 1 in 200,000 live births. However, it is lower in some areas, such as the United States and Europe, where it is expected to be 1 in 500,000-660,000 live births.
• ADA insufficiency is particularly widespread in some populations, such as Somalis and Amish/Mennonites.
• Each year, around one in every 58,000 babies in the United States is born with SCID.
• About 15 to 20 percent of patients with ADA deficiency suffer health problems that begin between one and ten years old (delayed onset) or in adulthood (late onset).

Drugs:

Revcovi (Elapegademase-Lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. REVCOVI is for intramuscular injections only.

Adagen (Pegademase Bovine) injection is a modified enzyme used in enzyme replacement therapy to treat severe combined immunodeficiency disease caused by adenosine deaminase deficiency. ADAGEN Injection is a sterile, isotonic, pyrogen-free solution with a pH range of 7.2-7.4 for intramuscular injection. The solution is packaged in 1.5 mL single-dose vials.

Strimvelis (autologous CD34+ enriched cell fraction containing CD34+ cells transduced with a retroviral vector encoding the human ADA cDNA sequence) is a gammaretroviral vector-based gene therapy authorized by the European Medicines Agency. Strimvelis is recommended for the treatment of individuals with severe combined immunodeficiency caused by adenosine deaminase deficiency (ADA-SCID) who do not have a suitable HLA-matched related stem cell donor available.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the adenosine deaminase-severe combined immunodeficiency market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the adenosine deaminase-severe combined immunodeficiency market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current adenosine deaminase-severe combined immunodeficiency marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the adenosine deaminase-severe combined immunodeficiency market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the adenosine deaminase-severe combined immunodeficiency market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the adenosine deaminase-severe combined immunodeficiency market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency across the seven major markets?
• What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of adenosine deaminase-severe combined immunodeficiency by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with adenosine deaminase-severe combined immunodeficiency across the seven major markets?
• What is the size of the adenosine deaminase-severe combined immunodeficiency patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of adenosine deaminase-severe combined immunodeficiency?
• What will be the growth rate of patients across the seven major markets?
   

Adenosine Deaminase-Severe Combined Immunodeficiency: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for adenosine deaminase-severe combined immunodeficiency drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the adenosine deaminase-severe combined immunodeficiency market?
• What are the key regulatory events related to the adenosine deaminase-severe combined immunodeficiency market?
• What is the structure of clinical trial landscape by status related to the adenosine deaminase-severe combined immunodeficiency market?
• What is the structure of clinical trial landscape by phase related to the adenosine deaminase-severe combined immunodeficiency market?
• What is the structure of clinical trial landscape by route of administration related to the adenosine deaminase-severe combined immunodeficiency market?